Results 51 to 60 of about 22,968 (195)

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. [PDF]

, 2016
Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are common features of most cancer types. CDKs have been shown to play important roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA ...
Duan, Zhenfeng, Hornicek, Francis J, Kan, Quancheng, Shen, Jacson K, Zhou, Yubing   +4 more
core   +1 more source

Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

Frontiers in Pharmacology, 2023
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (
Claudia Arndt, Claudia Arndt, Antje Tunger, Antje Tunger, Rebekka Wehner, Rebekka Wehner, Rebekka Wehner, Rebecca Rothe, Rebecca Rothe, Eleni Kourtellari, Stephanie Luttosch, Katharina Hannemann, Stefanie Koristka, Liliana R. Loureiro, Anja Feldmann, Torsten Tonn, Torsten Tonn, Torsten Tonn, Theresa Link, Theresa Link, Theresa Link, Jan Dominik Kuhlmann, Jan Dominik Kuhlmann, Jan Dominik Kuhlmann, Pauline Wimberger, Pauline Wimberger, Pauline Wimberger, Michael Philipp Bachmann, Michael Philipp Bachmann, Michael Philipp Bachmann, Michael Philipp Bachmann, Marc Schmitz, Marc Schmitz, Marc Schmitz   +33 more
doaj   +1 more source

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]

, 2019
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L, Elkin, Sheryl K, Ikeda, Sadakatsu, Kurzrock, Razelle, Tomson, Brett N   +4 more
core  

CDK4/6 inhibition in luminal breast cancer [PDF]

, 2016
Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease.
Gabriel Rinnerthaler, Richard Greil, Simon Peter Gampenrieder   +2 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. [PDF]

, 2018
Purpose: The retinoblastoma tumor suppressor (RB), a key regulator of cell-cycle progression and proliferation, is functionally suppressed in up to 50% of non-small cell lung cancer (NSCLC).
Addya, Sankar, Bhardwaj, Anshul, Birbe, Ruth, Chellappagounder, Thangavel, Den, Robert B., Dicker, Adam P., Ertel, Adam, Ettickan, Boopathi, Haber, Alex, Knudsen, Karen E., Liu, Yi, McNair, Christopher, Perepelyuk, Maryna, Salvino, Joseph M., Shoyele, Sunday   +14 more
core   +1 more source

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

npj Breast Cancer
Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with tamoxifen are ...
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori   +33 more
doaj   +1 more source

Risk Factors Influencing Efficacy and Prognosis Evaluation of Neoadjuvant Systemic Therapy in Triple‐Positive Breast Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT To identify the determinants of the response to neoadjuvant systemic therapy (NST) in triple‐positive breast cancer (TPBC), we retrospectively enrolled 520 patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who were treated at The First Affiliated Hospital of Chongqing Medical University between January 2015 ...
Lin‐Rui Miao, Hao Liu, Hai‐Ying Yu, Jian Chen, Ming‐Yu Yang, Ya‐Lan Zhang, Gang Tu, Ling‐Feng Tang   +7 more
wiley   +1 more source